Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 331

The DOI matches its Crossref record.

The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders

Leriche, L., Bezard, E., Gross, C., Guillin, O., Foll, B., Diaz, J., Sokoloff, P. · 2006 · CNS & Neurological Disorders - Drug Targets

Abstract

The role of the D(3) receptor has remained largely elusive before the development of selective research tools, such as selective radioligands, antibodies, various highly specific pharmacological agents and knock-out mice. The data collected so far with these tools have removed some of the uncertainties regarding the functions mediated by the D(3) receptor. The D(3) receptor is an autoreceptor that controls the phasic, but not tonic activity of dopamine neurons. The D(3) receptor, via regulation of its expression by the brain-derived neurotrophic factor (BDNF), mediates sensitization to dopamine indirect agonists. This process seems responsible for side-effects of levodopa (dyskinesia) in the treatment of Parkinson's disease (PD), as well as for some aspects of conditioning to drugs of abuse. The D(3) receptor mediates behavioral abnormalities elicited by glutamate/NMDA receptor blockade, which suggests D(3) receptor-selective antagonists as novel antipsychotic drugs. These data allow us to propose novel treatment options in PD, schizophrenia and drug addiction, which are awaiting evaluation in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/187152706784111551

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 331

Metadata

Authors
Leriche, L., Bezard, E., Gross, C., Guillin, O., Foll, B., Diaz, J., & Sokoloff, P.
Venue
CNS & Neurological Disorders - Drug Targets
Published
2006-02-01
Volume
5
Issue
1
Pages
25-43
ISSN
  • 1568-007X (ISSN-L)
  • 1871-5273
OpenAlex
W2110971533
Cited by
331
References
0
FWCI
8.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders. https://app.cochat.ai/papers/10.2174/187152706784111551
The paper
Leriche, L., Bezard, E., Gross, C., Guillin, O., Foll, B., Diaz, J., & Sokoloff, P. (2006). The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152706784111551

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.